John Adams to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications John Adams has written about Diabetes Mellitus, Type 2.
Connection Strength
0.650
-
Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis. BMJ Open Diabetes Res Care. 2024 May 06; 12(3).
Score: 0.570
-
The Comparison of Matching Methods Using Different Measures of Balance: Benefits and Risks Exemplified within a Study to Evaluate the Effects of German Disease Management Programs on Long-Term Outcomes of Patients with Type 2 Diabetes. Health Serv Res. 2016 Oct; 51(5):1960-80.
Score: 0.080